GSK: positive results for meningitis vaccine

(CercleFinance.com) - GSK announced on Thursday that it had recorded positive results from a phase III clinical trial of its experimental "5-in-1" vaccine against different strains of meningitis.


The British pharmaceutical company said the trial showed the product was non-inferior to previously licensed meningococcal vaccines.

The study, which began in 2020, enrolled 3,650 children, adolescents and young people aged 10 to 25 years in Canada, the US, Europe, Turkey and Australia.

This vaccine project was developed in the knowledge that five serogroups cause all cases of invasive meningococcal disease, but that no 5-in-1 vaccine currently exists.

While invasive meningococcal disease is uncommon, it is the leading cause of bacterial meningitis, a disease that results in death in about one in 10 cases, even with appropriate treatment.

In addition, about 20% of those affected are likely to have significant physical or neurological impairment in the long term, such as loss of a limb, hearing loss or seizures.


Copyright (c) 2023 CercleFinance.com. All rights reserved.